As the world waits for a SARS-CoV-2 vaccine, federal funding of biomedical research is more crucial than ever. During this COVID-19 pandemic, the National Institutes of Health (NIH) is committed to supporting not only the development of novel drugs to treat this virus but to continuing to fund the research of other groundbreaking vaccines, medicines, and therapies. Yet as new treatments to enhance – or save – our lives are discovered, how are the pricing structures determined?
In this interview-style webinar, Rep. Rosa DeLauro (D-CT), Chair of the Labor, Health and Human Services, and Education Appropriations Subcommittee, joins Triumvirate Environmental CEO John F. McQuillan for a dynamic discussion on novel drug development and pricing.
During this interview, Rep. DeLauro and Mr. McQuillan will explore topics
To register, please complete the form. You are encouraged to submit questions for Rep. DeLauro and Mr. McQuillan as you register. There will not be an opportunity to ask questions live during the event.